235 related articles for article (PubMed ID: 36243666)
21. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.
Hornberger J; Robertus K
Ann Intern Med; 2006 Sep; 145(5):317-25. PubMed ID: 16954357
[TBL] [Abstract][Full Text] [Related]
22. Recombinant zoster vaccine in immunocompetent and immunocompromised adults: A review of clinical studies.
Mwakingwe-Omari A; Lecrenier N; Naficy A; Curran D; Posiuniene I
Hum Vaccin Immunother; 2023 Dec; 19(3):2278362. PubMed ID: 37965770
[TBL] [Abstract][Full Text] [Related]
23. Cost-effectiveness of varicella vaccine against herpes zoster and post-herpetic neuralgia for elderly in Japan.
Hoshi SL; Kondo M; Okubo I
Vaccine; 2017 May; 35(24):3264-3271. PubMed ID: 28479176
[TBL] [Abstract][Full Text] [Related]
24. Cost-effectiveness of an adjuvanted recombinant zoster vaccine in older adults in the United States who have been previously vaccinated with zoster vaccine live.
Curran D; Patterson BJ; Van Oorschot D; Buck PO; Carrico J; Hicks KA; Lee B; Yawn BP
Hum Vaccin Immunother; 2019; 15(4):765-771. PubMed ID: 30625011
[TBL] [Abstract][Full Text] [Related]
25. Incremental clinical and economic impact of recombinant zoster vaccination: real-world data in a budget impact model.
Patterson BJ; Herring WL; Van Oorschot D; Curran D; Carrico J; Zhang Y; Ackerson BK; Bruxvoort K; Sy LS; Tseng HF
J Manag Care Spec Pharm; 2020 Dec; 26(12):1567-1575. PubMed ID: 33043821
[TBL] [Abstract][Full Text] [Related]
26. A practitioner's guide to the recombinant zoster vaccine: review of national vaccination recommendations.
Parikh R; Widenmaier R; Lecrenier N
Expert Rev Vaccines; 2021 Sep; 20(9):1065-1075. PubMed ID: 34311643
[TBL] [Abstract][Full Text] [Related]
27. The potential cost-effectiveness of vaccination against herpes zoster and post-herpetic neuralgia.
Brisson M; Pellissier JM; Camden S; Quach C; De Wals P
Hum Vaccin; 2008; 4(3):238-45. PubMed ID: 18382137
[TBL] [Abstract][Full Text] [Related]
28. Cost effectiveness of herpes zoster vaccine in Canada.
Najafzadeh M; Marra CA; Galanis E; Patrick DM
Pharmacoeconomics; 2009; 27(12):991-1004. PubMed ID: 19908924
[TBL] [Abstract][Full Text] [Related]
29. A systematic review of the cost effectiveness of herpes zoster vaccination.
Szucs TD; Pfeil AM
Pharmacoeconomics; 2013 Feb; 31(2):125-36. PubMed ID: 23335045
[TBL] [Abstract][Full Text] [Related]
30. Modeled impact of the COVID-19 pandemic and associated reduction in adult vaccinations on herpes zoster in the United States.
Curran D; La EM; Salem A; Singer D; Lecrenier N; Poston S
Hum Vaccin Immunother; 2022 Dec; 18(1):2027196. PubMed ID: 35049412
[TBL] [Abstract][Full Text] [Related]
31. Adjuvanted recombinant zoster vaccine in adult autologous stem cell transplant recipients: polyfunctional immune responses and lessons for clinical practice.
Stadtmauer EA; Sullivan KM; El Idrissi M; Salaun B; Alonso Alonso A; Andreadis C; Anttila VJ; Bloor AJ; Broady R; Cellini C; Cuneo A; Dagnew AF; Di Paolo E; Eom H; González-Rodríguez AP; Grigg A; Guenther A; Heineman TC; Jarque I; Kwak JY; Lucchesi A; Oostvogels L; Polo Zarzuela M; Schuind AE; Shea TC; Sinisalo UM; Vural F; Yáñez San Segundo L; Zachée P; Bastidas A
Hum Vaccin Immunother; 2021 Nov; 17(11):4144-4154. PubMed ID: 34406911
[TBL] [Abstract][Full Text] [Related]
32. The public health impact of recombinant herpes zoster vaccination in adults over 50 years in Spain.
García A; Vallejo-Aparicio LA; Cambronero Martinez R
Hum Vaccin Immunother; 2024 Dec; 20(1):2366353. PubMed ID: 38925145
[TBL] [Abstract][Full Text] [Related]
33. Safety Profile of the Adjuvanted Recombinant Zoster Vaccine in Immunocompromised Populations: An Overview of Six Trials.
López-Fauqued M; Co-van der Mee M; Bastidas A; Beukelaers P; Dagnew AF; Fernandez Garcia JJ; Schuind A; Tavares-da-Silva F
Drug Saf; 2021 Jul; 44(7):811-823. PubMed ID: 34115324
[TBL] [Abstract][Full Text] [Related]
34. Potential public health impact of the adjuvanted recombinant zoster vaccine among people aged 50 years and older in Beijing.
Lee C; Jiang N; Tang H; Ye C; Yuan Y; Curran D
Hum Vaccin Immunother; 2021 Oct; 17(10):3735-3746. PubMed ID: 34310268
[TBL] [Abstract][Full Text] [Related]
35. Herpes zoster vaccine: A health economic evaluation for Switzerland.
Blank PR; Ademi Z; Lu X; Szucs TD; Schwenkglenks M
Hum Vaccin Immunother; 2017 Jul; 13(7):1495-1504. PubMed ID: 28481678
[TBL] [Abstract][Full Text] [Related]
36. Projected risks and health benefits of vaccination against herpes zoster and related complications in US adults.
Janusz CB; Anderson TC; Leidner AJ; Lee GM; Dooling K; Prosser LA
Hum Vaccin Immunother; 2022 Nov; 18(5):2060668. PubMed ID: 35476029
[TBL] [Abstract][Full Text] [Related]
37. Health economic evaluation of a vaccine for the prevention of herpes zoster (shingles) and post-herpetic neuralgia in adults in Belgium.
Annemans L; Bresse X; Gobbo C; Papageorgiou M
J Med Econ; 2010; 13(3):537-51. PubMed ID: 20707768
[TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness analysis of a vaccination program for the prevention of herpes zoster and post-herpetic neuralgia in adults aged 50 and over in Germany.
Préaud E; Uhart M; Böhm K; Aidelsburger P; Anger D; Bianic F; Largeron N
Hum Vaccin Immunother; 2015; 11(4):884-96. PubMed ID: 25933182
[TBL] [Abstract][Full Text] [Related]
39. Recombinant Zoster Vaccine Significantly Reduces the Impact on Quality of Life Caused by Herpes Zoster in Adult Autologous Hematopoietic Stem Cell Transplant Recipients: A Randomized Placebo-Controlled Trial (ZOE-HSCT).
Curran D; Matthews S; Rowley SD; Young JH; Bastidas A; Anagnostopoulos A; Barista I; Chandrasekar PH; Dickinson M; El Idrissi M; Heras I; Milliken ST; Monserrat Coll J; Navarro Matilla MB; Oostvogels L; Piątkowska-Jakubas B; Quiel D; Sabry W; Schwartz S; Selleslag DLD; Sullivan KM; Theunissen K; Yegin ZA; Yeh SP; Zaja F; Szer J;
Biol Blood Marrow Transplant; 2019 Dec; 25(12):2474-2481. PubMed ID: 31394276
[TBL] [Abstract][Full Text] [Related]
40. Zoster vaccine (Zostavax): a review of its use in preventing herpes zoster and postherpetic neuralgia in older adults.
Sanford M; Keating GM
Drugs Aging; 2010 Feb; 27(2):159-76. PubMed ID: 20104941
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
